Clinical trials: Epirubicin
Multiple Myeloma
A Study of PAD Versus Velcade, Cyclophosphamide and Dexamethasone (VCD) Treatment in Subjects With Multiple Myeloma
A multicenter, double arms, prospective randomized controlled phase 4 study. Approximately 50 previously untreated subjects with multiple myeloma will be enrolled.
- Trial name
- NCT01868828
- Testing
- PAD, VCD, ASCT
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Peking University People's Hospital
Urothelial Carcinoma, Bladder Cancer
Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma
Background: Advanced urothelial cancer has no cure. But only a few chemotherapy drugs have been tested for it. The Co-eXpression ExtrapolatioN (COXEN) model predicts if cells respond to treatment.
- Conditions
- Urothelial Carcinoma, Bladder Cancer, Urinary Bladder Neoplasms
- Trial name
- NCT02788201
- Testing
- 75 approved agents, COXEN
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- National Cancer Institute (NCI)
The First Affiliated Hospital of Nanchang University
A Study of Orelabrutinib Plus R-CHOP in Treatment-naïve Patients With Double Expression Diffuse Large B-cell Lymphoma
This is a multicenter prospective single arm phase II study, and the purpose of this study is to evaluate the safety and efficacy of orelabrutinib combined with R-CHOP in the treatment of treatment-naïve patients with double…
- Trial name
- NCT05933967
- Testing
- Orelabrutinib+R-CHOP
- Where
- 2 sites in China
- Volunteers
- 31 people
- Sponsor
- Shandong Cancer Hospital and Institute
Germ Cell Tumor
Phase II Study of Cisplatin Plus Epirubicin Salvage Chemo in Refractory Germ Cell Tumors
This study proposes to evaluate the combination of cisplatin plus epirubicin in patients with refractory germ cell tumor not amendable to cure with surgery or standard platinum salvage chemotherapy.
- Trial name
- NCT00198172
- Testing
- Cisplatin plus Epirubicin
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Indiana University
Hepatocellular Carcinoma Non-resectable
DEB-TACE vs. cTACE as Conversion Therapy for Unresectable Large HCC
This study is conducted to evaluate the efficacy of drug-eluting bead transarterial chemoembolization (DEB-TACE) compared with conventional transarterial chemoembolization (cTACE) as the conversion therapy for unresectable large…
- Trial name
- NCT04967482
- Testing
- Drug-eluting bead transarterial chemoembolization (DEB-TACE), Conventional transarterial chemoembolization (cTACE)
- Where
- China
- Volunteers
- 216 people
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
Bladder Cancer, Epirubicin Adverse Reaction
Comparison of the Efficacy and Safety of Continuous and Single-Dose Intravesical Epirubicin Instillation
In this study, the local and systemic side effects, tumor recurrens and progression rates of single or continuous epirubicin instillation during the early postoperative period were investigated in low and intermediate risk…
- Conditions
- Bladder Cancer, Epirubicin Adverse Reaction, Superficial Bladder Cancer, Tumor Recurrence
- Trial name
- NCT05084586
- Testing
- Intravesical Solution
- Where
- Turkey (Türkiye)
- Volunteers
- 100 people
- Sponsor
- Ankara Training and Research Hospital
Solid Tumor, Soft Tissue Sarcoma
Dose-Escalation and Expansion Trial of NC-6300 in Patients With Advanced Solid Tumors or Soft Tissue Sarcoma
The goal of this study is to find the highest tolerated dose of NC-6300 that can be given to patients with advanced solid tumors or soft tissue sarcoma. The safety and tolerability of the drug will also be studied.
- Conditions
- Solid Tumor, Soft Tissue Sarcoma, Metastatic Sarcoma, Sarcoma
- Trial name
- NCT03168061
- Testing
- NC 6300
- Where
- 7 sites in United States
- Volunteers
- 150 people
- Sponsor
- NanoCarrier Co., Ltd.
Breast Cancer
Pre-operative Chemotherapy in Operable Breast Cancer, Phase III Study Comparing a Short Intensive Pre-operative Chemotherapy With the Same Therapy Initiated Shortly After Surgery(Peri-operatively)(POCOB)EORTC 10902)
Pre-operative chemotherapy in operable breast cancer, phase III study comparing a short intensive pre-operative chemotherapy with the same therapy initiated shortly after surgery (peri-operatively) (POCOB) (EORTC 10902)
- Trial name
- NCT00544505
- Testing
- Fluorouracil/Epirubicin/Cyclophosphamide
- Volunteers
- 10 people
- Sponsor
- King Faisal Specialist Hospital & Research Center
Metastatic Breast Cancer
A Pilot Dose Escalation Trial of a Densified Chemotherapy Association of Docetaxel and Epirubicin Driven by Mathematical Modeling in Metastatic Breast Cancer Patients: The MODEL1 Study
To determine the maximum tolerated dose of a densified regimen of the association of docetaxel (DTX) and epirubicin (EPI), supported by the concomitant administration of hematopoietic growth factors in patients with metastatic…
- Trial name
- MODEL1 (NCT02392845)
- Testing
- Combination of Docetaxel (DTX) and Epirubicin (EPI)
- Where
- France
- Volunteers
- 17 people
- Sponsor
- Hospices Civils de Lyon
Triple-negative Breast Cancer
Carboplatin Intensified Chemotherapy for TRIple NEgative Breast Cancer(CITRINE)
This is a prospective, single center, randomized, open-labled stage III clinical trial comparing the efficacy and safety of anthracyclin followed by weekly paclitaxel versus dose-dense anthracyclin followed by weekly paclitaxel…
- Trial name
- CITRINE (NCT04296175)
- Testing
- Epirubicin, CTX, Paclitaxel
- Where
- China
- Volunteers
- 808 people
- Sponsor
- Fudan University
Gastric Cancer, Gastroesophageal Cancer
Overall Survival of Inoperable Gastric/GastroOesophageal Cancer Subjects on Treating With LMWH + Chemotherapy(CT) vs Standard CT
Due to evidence available both in terms of efficacy and safety of low molecular weight heparin, its use for the prevention of thromboembolic disease in cancer patients undergoing surgical intervention, and its extended use in…
- Trial name
- GASTRANOX (NCT00718354)
- Testing
- Enoxaparin, Standard Chemotherapy
- Where
- 15 sites in India
- Volunteers
- 740 people
- Sponsor
- Thrombosis Research Institute
Triple-negative Breast Cancer
Study to Compare a Mono Atezolizumab Window Followed by a Atezolizumab - CTX Therapy With Atezolizumab - CTX Therapy
This is a randomized, open-label, adaptive, two arm, multicentre, Phase II trial comparing a neoadjuvant chemotherapy with PDL1-inhibition (Atezolizumab) and Atezolizumab two-week window to chemotherapy with PDL1-inhibition…
- Trial name
- neoMono (NCT04770272)
- Testing
- Atezolizumab 840 MG in 14 ML Injection, Atezolizumab 1200 MG in 20 ML Injection, Carboplatin
- Where
- Germany
- Volunteers
- 442 people
- Sponsor
- Palleos Healthcare GmbH
Breast Cancer, Chemotherapy-induced Alopecia
PBMT for the Management of CIA ( HAIRLASER )
Chemotherapy (CT) remains an important treatment modality for breast cancer patients. Unfortunately, this systemic treatment comes with many quality of life impairing complications.
- Conditions
- Breast Cancer, Chemotherapy-induced Alopecia, Alopecia
- Trial name
- NCT04036994
- Testing
- Photobiomodulation therapy
- Where
- Belgium
- Volunteers
- 30 people
- Sponsor
- Hasselt University
Breast Cancer
Epirubicin and Docetaxel in the Treatment of Patients With Metastatic Breast Cancer
The epirubicin/docetaxel combination is one of the most active and best tolerated taxane/anthracycline combinations. In this phase II trial, we will further evaluate the feasibility, safety and effectiveness of the…
- Trial name
- NCT00193024
- Testing
- Docetaxel, Epirubicin
- Volunteers
- 90 people
- Sponsor
- SCRI Development Innovations, LLC
Adenocarcinoma of Oesophagus
Pre-operative Epirubicin, Cisplatin, and Capecitabine in Patients With Newly Diagnosed Localised Oesophageal Adenocarcinoma
To investigate the efficacy and safety of epirubicin, cisplatin and capecitabine as neoadjuvant therapy prior to radical resection in patients with newly diagnosed operable oesophageal adenocarcinoma.
- Trial name
- NCT00220103
- Testing
- epirubicin, capecitabine, cisplatin, Surgical resection
- Where
- United Kingdom
- Volunteers
- 80 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Bladder Cancer, Gemcitabine and Cisplatin Chemotherapy
Transurethral Resection of Bladder Tumor (TURBT) Combined With Adjuvant Intravenous GC Chemotherapy for Non-muscle-invasive Bladder Cancer
It is still a challenge for urologic surgeon to prevent the post transurethral resection of bladder tumor (TURBT) recurrence of moderate-high risk non-muscle invasive bladder tumor.
- Conditions
- Bladder Cancer, Gemcitabine and Cisplatin Chemotherapy, Epirubicin Instillation, Recurrence
- Trial name
- NCT02716961
- Testing
- Gemcitabine, cisplatin
- Where
- China
- Volunteers
- 208 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Hormone Receptor Positive HER-2 Negative Breast Cancer
TCb vs EC-T in High Risk ER+/HER2- Breast Cancer
This study will evaluate the efficacy and safety of docetaxel plus carboplatin (TCb) regimen compared with conventional chemotherapy regimen (epirubicin plus cyclophosphamide followed by docetaxel, EC-T) regimen as adjuvant…
- Trial name
- NCT05901428
- Testing
- Docetaxel, Carboplatin, Epirubicin
- Where
- China
- Volunteers
- 1,736 people
- Sponsor
- Fudan University
Adenoid Cystic Carcinoma
Neoadjuvant Anlotinib and Epirubicin for T4 Sinonasal Adenoid Cystic Carcinoma
T4 stage sinonasal adenoid cystic carcinoma (SNACC) is a rare but aggressive cancer in the nasal cavity and sinuses. These tumors often invade the skull base, eye socket, or brain covering (dura), making complete surgical removal…
- Trial name
- NAET4-SNACC (NCT07616141)
- Testing
- Anlotinib Hydrochloride, Epirubicin
- Where
- 5 sites in China
- Volunteers
- 76 people
- Sponsor
- Eye & ENT Hospital of Fudan University
Adenocarcinoma of the Gastroesophageal Junction, Gastric Cancer
Epirubicin Hydrochloride, Cisplatin, and Fluorouracil or Capecitabine With or Without Lapatinib Ditosylate as First-Line Therapy in Treating Patients With Stomach Cancer or Gastroesophageal Junction Cancer
RATIONALE: Drugs used in chemotherapy, such as epirubicin hydrochloride, cisplatin, fluorouracil, and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from…
- Trial name
- NCT01123473
- Testing
- capecitabine, cisplatin, epirubicin hydrochloride
- Where
- 4 sites in Belgium, Germany and 1 more
- Volunteers
- 29 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Triple Negative Breast Cancer
Clinical Trial of Neoadjuvant Chemotherapy With Atezolizumab or Placebo in Patients With Triple-Negative Breast Cancer Followed After Surgery by Atezolizumab or Placebo
The main purpose of this study is to learn if the usual chemotherapy given before surgery (neoadjuvant therapy) for breast cancer plus the experimental drug, atezolizumab, is better than the usual chemotherapy plus a placebo.
- Trial name
- NCT03281954
- Testing
- Atezolizumab
- Where
- 217 sites in United States, Canada
- Volunteers
- 1,550 people
- Sponsor
- NSABP Foundation Inc